The Eyes Still Have It For Novartis Despite Sell-Off Rumors
Some Ophthalmology Assets Reported To Be Up For Grabs
Rumors have resurfaced that Novartis is looking to shift some of its eye drugs but the Basle-based behemoth tells Scrip it remains committed to in-market products and R&D projects in the ophthalmology space.
